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demonstrate that the risk of cardiovascular diseases
and death rises in graded fashion with increasing blood
pressure (Mosterd et al., 1999; Kannel, 2000). While hy-
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Departments of Genetics, Medicine, pertension was once thought to be “essential” for perfu-
sion of tissues through sclerotic and narrowed bloodand Molecular Biophysics and Biochemistry
Yale University School of Medicine vessels, the pathologic nature of elevated blood pres-
sure is now clear. Randomized controlled trials of phar-New Haven, Connecticut
†Department of Medicine macologic treatment of hypertension have documented
that blood pressure reduction lowers morbidity and mor-Mount Sinai School of Medicine
New York, New York tality, with dramatic reduction in stroke and smaller re-
ductions in myocardial infarction (Multiple Risk Factor
Intervention Trial Research Group, 1982; Medical Re-
search Council Working Party, 1985). As a result of suchIntroduction
studies, elevated blood pressure, or hypertension, hasHypertension, or elevated arterial blood pressure, is a
been operationally defined as the blood pressure levelsubstantial public health problem, affecting 25% of the
above which therapeutic intervention has clinical bene-adult population in industrialized societies (Burt et al.,
fit. As increasingly aggressive intervention has contin-1995). This disorder is a major risk factor for many com-
ued to demonstrate benefit, this level has gradually re-mon causes of morbidity and mortality including stroke,
duced over time and is commonly defined at presentmyocardial infarction, congestive heart failure, and end-
as levels above 140/90 mm Hg in adults. These observa-stage renal disease (Mosterd et al., 1999; USRDS, 1999;
tions leave open the question of whether there is anKannel, 2000). Despite the important role of hyperten-
“optimal” blood pressure, and whether small reductionssion as a cause of disease, its pathogenesis remains
in blood pressure across the entire population, ratherlargely unknown. Recently, the application of genetic
than larger targeted reductions, would have benefit.approaches to this disease has begun to delineate mo-
lecular pathways underlying blood pressure variation,
defining disease pathogenesis and identifying targets
Epidemiology and Physiologyfor therapeutic intervention. This review focuses on the
Substantial effort has been devoted to defining themolecular mechanisms that have been implicated in
pathogenesis of blood pressure variation. Epidemio-blood pressure variation in humans.
logic studies have documented the impact of a varietyEach cycle of cardiac contraction propels a bolus
of factors, including age, gender, and body mass indexof 70 mls of blood into the systemic arterial system,
(Stanton et al., 1982). Diet has also been implicated, withperfusing organs with oxygen and nutrients. This propul-
salt, potassium, and calcium suggested as importantsion imparts pressure on the vascular wall, the level of
factors (Appel et al., 1997). How these factors influencepressure depending solely upon the cardiac output (the
physiology to alter blood pressure has been the subjectamount of blood pumped by the heart) and the resis-
of extensive investigation.tance to flow imparted by the vasculature. Because of
The physiology of blood pressure determination isthe episodic ejection of blood from the heart, pressure
deceptively simple, following Ohm’s law (blood pressurein the vessels shows periodic variation, being highest
is proportional to cardiac output and vascular resistanceat the peak of a passing bolus of blood, and lowest
to blood flow). Nonetheless, a wide variety of physiologicafter its passage. These respective peak and trough
systems that have pleiotropic effects and interact inpressures correspond to the systolic and diastolic pres-
complex fashion have been found to influence bloodsures that can be measured intraarterially or more com-
pressure. Included among these systems are barore-monly by a blood pressure cuff. Population studies dem-
ceptors that sense acute changes in pressure in vessels;onstrate that levels of blood pressure in the population
natriuretic peptides produced by the brain and heart inshow a continuous distribution.
response to increased pressure in these organs; theBlood pressure must be tightly regulated to permit
renin-angiotensin-aldosterone system, which influencesuninterrupted perfusion of all vital organs. For example,
vascular volume homeostasis and vascular tone; theeven transient interruption in blood flow to the brain will
kinin-kallikrein system, which affects vascular tone andcause loss of consciousness, and longer interruptions
renal salt handling; the adrenergic receptor system,will result in death of unperfused tissues. Conversely,
which influences heart rate, cardiac contraction, andhigher pressures that deliver flow exceeding metabolic
vascular tone; and factors produced by blood vesselsdemand provide little or no metabolic gain, but increase
that cause vasodilation, such as nitric oxide, or contrac-damage to blood vessels and organs. These consider-
tion, such as endothelin. These systems act in an inte-ations dictate the normal ranges of blood pressure.
grated fashion to ensure adequate perfusion of all tis-The morbid consequences of high blood pressure
sues despite widely varying metabolic demand. Thehave been documented by epidemiologic studies, which
contributions of some of these systems to short-term
blood pressure control has been extensively studied‡ To whom correspondence should be addressed (e-mail: richard.
lifton@yale.edu). and established. For example, acute decreases in blood
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pressure trigger an integrated neurohumoral response large effects on blood pressure. This approach may be
particularly well suited to hypertension, as success maythat rapidly restores normal pressure by increasing heart
rate, cardiac contractility (the strength of cardiac con- define fundamental pathways which, when altered, af-
fect blood pressure in humans. It is in this arena thattraction), and vascular tone.
While the role of many of these systems has been the most progress has been made to date.
established for short-term homeostatic responses, de-
termining which, if any, of these pathways contributes Mendelian Forms of Blood Pressure Variation
to long-term blood pressure determination has proved Molecular genetic studies have now identified mutations
more problematic. Since blood pressure can only be in 8 genes that cause Mendelian forms of hypertension
measured in intact living organisms in which these phys- and 9 genes that cause Mendelian forms of hypotension
iologic systems interact in complex fashion, distinguish- in humans. These genes typically impart very large ef-
ing primary alterations from adaptive secondary re- fects on blood pressure. Given the diversity of physio-
sponses has proved difficult from physiologic analysis logic systems that affect blood pressure, it is perhaps
alone. As a result, the primary abnormalities underlying surprising that the mutated gene products in all cases
blood pressure variation remain unknown. Treatment act in the same physiologic pathway in the kidney, alter-
of hypertension is consequently largely empiric, with ing net renal salt reabsorption. The elements of salt
physicians selecting from approximately 70 different an- homeostasis and their link to blood pressure is de-
tihypertensive medications until adequate blood pres- scribed briefly below.
sure reduction is achieved. Owing to the high prevalence In a normal day, the kidneys filter over 170 liters of
of hypertension, the inability to tailor treatment to spe- plasma containing 23 moles of salt. Therefore, mainte-
cific underlying abnormalities, the need for continued nance of salt homeostasis on a typical 100 meq sodium
treatment and follow-up, and the attendant morbidity, diet requires that the kidneys reabsorb 99.5% of the
the care of patients with hypertension is one of the filtered salt. This is accomplished by an integrated sys-
largest expenses in the US health care budget. tem of ion channels, exchangers, and transporters (Fig-
ure 1). Sixty percent of the filtered sodium is reabsorbed
in the proximal tubule (PT) of the nephron, largely byEvidence for Genetic Effects
The difficulty in defining the causes of hypertension from Na1/H1 exchange. Thirty percent is reabsorbed in the
thick ascending limb of Henle (TAL) by Na-K-2Cl co-physiologic studies alone has motivated the application
of genetic approaches to hypertension. Identification transport. Seven percent is reclaimed by Na-Cl cotrans-
port in the distal convoluted tubule (DCT). The last 2%of genes underlying blood pressure variation has the
capacity to define primary physiologic mechanisms un- is reabsorbed via the epithelial Na1 channel (ENaC) in
the cortical collecting tubule (CCT).derlying this trait, thereby clarifying disease pathogene-
sis, identifying pathways and targets for therapeutic inter- While this last step accounts for only a small fraction
of salt reabsorption, this is the principal site at whichvention, providing opportunity for preclinical diagnosis,
and allowing treatment tailored to underlying abnormali- net salt balance is normally determined, as the activity of
this channel is highly regulated by the renin-angiotensinties in individual patients. There is substantial evidence
for genetic influence on blood pressure. Twin studies system (Figure 1). Decreased delivery of salt to the thick
ascending limb of Henle leads to increased secretiondocument greater concordance of blood pressures of
monozygotic than dizygotic twins (Feinleib et al., 1977), of the aspartyl protease renin, which results in increased
formation of the short peptide hormone angiotensin IIand population studies demonstrate greater similarity
of blood pressure within families than between families (AII). AII binds to its specific G protein–coupled receptor
in the adrenal glomerulosa, inducing secretion of aldo-(Longini et al., 1984). This familial aggregation of blood
pressure is not simply attributable to shared environ- sterone, the principal mineralocorticoid steroid hor-
mone. Aldosterone binds to the mineralocorticoid re-mental effects since adoption studies show greater con-
cordance of blood pressure among biological siblings ceptor (MR), a nuclear hormone receptor in principal
cells of the distal nephron, initiating a sequence ofthan adoptive siblings living in the same household
(Biron et al., 1976; Rice et al., 1989). Finally, that single events that leads to increased activity of ENaC and
increased salt reabsorption.genes can impart large effects on blood pressure is
demonstrated by rare Mendelian forms of high and low Mutations in many steps of this pathway have now
been identified by investigation of rare families featuringblood pressure (Lifton, 1996).
A number of approaches to the genetics of hyperten- severely high or severely low blood pressure, thereby
establishing the central role of this pathway in the long-sion can be contemplated. Studies of blood pressure
variation in the general population are complicated by term determination of blood pressure. Mutations that
increase renal salt reabsorption raise blood pressure;multifactorial determination, with a variety of demo-
graphic, environmental, and genetic factors contributing conversely, those that diminish salt reabsorption lower
blood pressure (Figure 1). In a number of cases, gain-to the trait in any single individual (Risch and Merikan-
gas, 1996). The absence of even rough estimates of of-function and loss-of-function mutations in the same
gene have been identified that have opposite effects onthe number of genes that influence the trait and the
magnitude of the effect imparted by any single locus blood pressure. The pathophysiologic link between salt
and blood pressure is predictable from the relationshiphas made optimal study design in the general population
a matter of conjecture. An alternative approach has been between salt and vascular volume homeostasis. In-
creased net renal salt reabsorption necessitates in-the investigation of rare Mendelian forms of blood pres-
sure variation in which mutations in single genes impart creased water reabsorption in order to maintain plasma
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Figure 1. Mutations Altering Blood Pressure in Humans
A diagram of a nephron, the filtering unit of the kidney, is shown. The molecular pathways mediating NaCl reabsorption in individual renal
cells in the thick ascending limb of the loop of Henle (TAL), distal convoluted tubule (DCT), and the cortical collecting tubule (CCT) are
indicated, along with the pathway of the renin-angiotensin system, the major regulator of renal salt reabsorption. Inherited diseases affecting
these pathways are indicated, with hypertensive disorders in red and hypotensive disorders in blue. Abbreviations: AI, angiotensin I; ACE,
angiotensin converting enzyme; AII, angiotensin II (AII); MR, mineralocorticoid receptor; GRA, glucocorticoid-remediable aldosteronism; PHA1,
pseudohypoaldosteronism, type-1; AME, apparent mineralocorticoid excess; 11 bHSD2, 11b-hydroxysteroid dehydrogenase-2; DOC, deoxy-
corticosterone; and PT, proximal tubule.
sodium concentration at or near 140 mM. The resulting Mutations Affecting Circulating
increased intravascular volume augments venous blood Mineralocorticoid Hormones
return to the heart, thereby raising cardiac output and The mineralocorticoid receptor, the major regulator of
leading directly to elevated blood pressure (Figure 2). ENaC activity, is normally activated by the steroid hor-
Conversely, impaired reabsorption of salt reduces blood mone aldosterone. A number of diseases result from
volume and blood pressure. abnormalities in aldosterone secretion or production of
other steroids that activate MR.
Glucorticoid-Remediable Aldosteronism
Glucocorticoid-remediable aldosteronism (GRA) is an
autosomal dominant trait featuring early onset of hyper-
tension with normal or elevated aldosterone levels de-
spite suppressed plasma renin activity (Sutherland et
al., 1966). Hypokalemia (low serum potassium level) and
metabolic alkalosis (elevated blood pH) are variable as-
sociated findings (Rich et al., 1992). The hallmark of this
disease, however, is that exogenous glucocorticoids
completely suppress aldosterone secretion. GRA is
caused by a gene duplication arising by unequal crossing
over between two closely related genes involved in adrenal
steroid biosynthesis. These genes encode aldosterone
synthase (the rate limiting enzyme for aldosterone bio-Figure 2. A Final Common Pathway for the Pathogenesis of Hyper-
synthesis in adrenal glomerulosa) and steroid 11b-hy-tension
droxylase, an enzyme involved in cortisol biosynthesisAll inherited and acquired forms of hypertension share increased
net salt balance as an inciting factor. Increased intravascular volume in the adrenal fasciculata whose expression is regulated
and volume delivery to the heart augment cardiac output and there- by adrenocorticotropic hormone (ACTH) (Figure 3; Lifton
fore blood pressure. The resulting tissue perfusion exceeds meta- et al., 1992a, 1992b). The resulting chimeric gene en-
bolic demand, leading to autoregulation of blood flow via increased
codes a protein with aldosterone synthase enzymaticvasoconstriction, resulting in a steady-state hemodynamic pattern
activity whose expression is regulated by ACTH. Aldo-of elevated blood pressure with increased systemic vascular resis-
tance and normal cardiac output. Nl, normal. sterone synthase activity is thus ectopically expressed
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hydroxysteroid dehydrogenase (11bHSD; Ulick et al.,
1979). The significance of this finding remained obscure
until the cloning of MR (Arriza et al., 1987). In vivo, corti-
sol circulates at concentrations up to 1000-fold higher
than aldosterone, however almost all MR activation in
vivo is mediated by aldosterone. It consequently came
as a surprise that in vitro, cortisol activated MR with
potency similar to aldosterone. This observation, com-
bined with the biochemical findings in AME, suggested
that the specificity of MR for aldosterone in vivo is medi-
ated indirectly, with 11bHSD “protecting” MR from corti-
sol by metabolizing it to cortisone, which does not acti-Figure 3. Chimeric Gene Duplication Underlying Glucocorticoid-
Remediable Aldosteronism vate MR (Funder et al., 1987; Stewart et al., 1987). In
The structure of the segment of chromosome 8 containing the aldo- AME, the absence of this enzyme allows cortisol to acti-
sterone synthase and steroid 11-b hydroxylase genes is shown. vate MR, resulting in hypertension mediated by in-
These two genes are nearly identical in DNA sequence and are creased ENaC activity. Confirmation of the pathogene-
closely linked in genomic DNA. One of the progeny chromosomes sis of AME came with the cloning of 11bHSD-2; this
resulting from unequal crossing over between these two genes car-
gene, expressed in the same cells of the nephron thatries a gene duplication that fuses regulatory sequences of the 11-
express ENaC, shows homozygous loss-of-functionhydroxylase gene to coding sequences conferring aldosterone syn-
thase enzymatic activity on the encoded gene product. mutations in AME patients (Mune et al., 1995).
These findings explain the pathogenesis of hyperten-
sion in AME and also the development of hypertension
in several other settings. Chronic ingestion of largein the adrenal fasciculata under control of ACTH rather
quantities of natural licorice results in hypertension withthan AII, the normal hormonal regulator. As a conse-
suppressed renin and aldosterone due to the action ofquence, aldosterone secretion becomes inexorably
a licorice metabolite, glycerrhetinic acid (Stewart et al.,linked to cortisol secretion, and maintenance of normal
1987). This compound is a potent inhibitor of 11bHSD,cortisol levels results in constitutive aldosterone secre-
producing a phenocopy of AME. Similarly, overproduc-tion, which leads to expanded plasma volume and hy-
tion of cortisol due to adenomas of the adrenal or pitu-pertension. The expanded plasma volume suppresses
itary glands, or due to inherited loss of the glucocorticoidsecretion of renin, but this fails to diminish secretion of
receptor (Hurley et al., 1991) is also complicated by hyper-aldosterone. Moreover, the increased lumen-negative
tension associated with low renin and aldosterone levels.potential resulting from increased electrogenic Na1 re-
The hypertension in these settings may be explained byabsorption increases the driving force for secretion of K1
the high circulating cortisol levels outstripping the abilityand H1, accounting for the development of hypokalemia
of 11bHSD to convert cortisol to cortisone, resulting inand metabolic alkalosis.
cortisol-mediated activation of MR.Defective Aldosterone Synthesis
In addition, other 21-hydroxylated steroids such asConversely, mutations resulting in loss of aldosterone
deoxycorticosterone and corticosterone are potent acti-synthase activity lead to impaired aldosterone biosyn-
vators of MR, but normally circulate at levels too low tothesis (Mitsuuchi et al., 1992; Pascoe et al., 1992). Indi-
activate the receptor in vivo. Inherited deficiencies inviduals harboring two defective gene copies have a mir-
steroid 11b-hydroxylase and 17a-hydroxylase impairror image of the GRA phenotype, with severely impaired
cortisol biosynthesis, diverting steroid synthesis intorenal salt retention and impaired secretion of K1 and
pathways proximal to the enzymatic block, resulting inH1 in the distal nephron. These individuals often present
overproduction of 21-hydroxylated steroids, with conse-with severe hypotension and shock due to reduced in-
quent hypertension and other endocrine abnormalitiestravascular volume. Similarly, deficiency in steroid 21-
(Figure 1; Kagimoto et al., 1988; White et al., 1991).hydroxylase also results in the absence of circulating
aldosterone with consequent salt wasting (excessive
renal salt loss), in addition to other endocrine abnormali- Mutations in the Mineralocorticoid Receptor
Hypertension Exacerbated in Pregnancyties (Figure 1; Bongiovanni and Root, 1963; Amor et al.,
1988). A mutation in the ligand binding domain of the mineralo-
corticoid receptor (MR) causes an autosomal dominantSyndrome of Apparent Mineralocorticoid Excess
There are several diseases in which steroids other than form of hypertension that is markedly accelerated in
pregnancy (Geller et al., 2000). The missense mutation,aldosterone activate MR. One of these is the syndrome
of apparent mineralocorticoid excess (AME). This au- MR S810L, was found in a single patient during a system-
atic screen of MR in patients with early onset hyperten-tosomal recessive disease features early onset hyper-
tension with hypokalemia and metabolic alkalosis ac- sion. Examination of the patient’s family demonstrated
that MR-L810 carriers all developed hypertension beforecompanied by suppressed plasma renin activity and the
virtual absence of circulating aldosterone. Antagonists age 20, a finding absent among their wild-type relatives.
Biochemical investigation of the mutant receptor dem-of MR lower blood pressure in these patients, sug-
gesting the presence of another circulating mineralocor- onstrated partial activation in the absence of added
steroid, but otherwise normal activation by aldosterone.ticoid (New et al., 1977). While biochemical investigation
failed to identify an abnormal steroid in the circulation, Surprisingly, however, compounds that normally bind,
but do not activate MR are all potent agonists of theaffected patients showed impaired conversion of corti-
sol to cortisone due to absence of the enzyme 11b- mutant receptor. This includes steroids lacking 21-
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hydroxyl groups, such as progesterone, and clinically
used antagonists of MR, such as spironolactone.
Since progesterone levels rise 100-fold during preg-
nancy, this observation suggested that patients harbor-
ing MR-L810 might develop severe hypertension in
pregnancy. Indeed, all pregnancies among patients har-
boring this mutation have been complicated by dramatic
acceleration of hypertension associated with complete
suppression of the renin-angiotensin system (Geller et
al., 2000). This observation that the abnormal action of
a normal hormone of pregnancy can underlie this trait
raises the question of whether related mechanisms may
Figure 4. Molecular Mechanism of Liddle Syndromeunderlie other forms of hypertension in pregnancy, a
The epithelial sodium channel is shown on the apical membrane ofcomplication occurring in 6% of all pregnancies and a
cells of the distal nephron. The clearance of the normal channel
major cause of maternal and fetal morbidity (August and from the membrane is dependent upon the sequence PPPXY in the
Lindheimer, 1995). cytoplasmic C terminus of both the b and g ENaC subunits. Loss
The mechanism by which MR-L810 allows MR activa- of this sequence from either subunit in Liddle syndrome results
in prolongation of the cell surface half-life and increased channeltion by steroids lacking 21-hydroxyl groups has been
number, attributable to loss of interaction with WW domain–containingexamined by molecular modeling and site-directed mu-
proteins and loss of clearance through clathrin-coated pits.tagenesis. The results demonstrate that the L810 resi-
due in helix 5 of the ligand binding domain makes a new
van der Waals interaction with A773 in helix 3, and that renin activity, and low plasma aldosterone levels. This
this interaction eliminates the requirement for the 21- disease is caused by mutations in either the b or the g
OH group of aldosterone to interact with N770 in helix subunit of ENaC that delete their cytoplasmic C termini
3. Intriguingly, every other steroid hormone receptor, as (Shimkets et al., 1994; Hansson et al., 1995a). These
well as a number of other nuclear hormone receptors mutations result in increased ENaC activity (Schild et al.,
have leucine-alanine or methionine-glycine pairs at ho- 1995), largely attributable to an increase in the number of
mologous positions in helix 5 and helix 3 that make van channels at the cell surface (Snyder et al., 1995). Rare
der Waals contacts. This observation suggests the vital missense mutations in patients identified a segment in
role of helix 5–helix 3 interaction in activation of nuclear the C termini, PPPXY, that when mutated gave the same
receptors and hints at a general approach to creation phenotype (Hansson et al., 1995b; Inoue et al., 1998).
of steroid receptor antagonists (Geller et al., 2000). Systematic site-directed mutagenesis of channel sub-
Autosomal Dominant PHA1 units indicates that mutations of any of these residues
Pseudohypoaldosteronism type I (PHAI) features severe yields an increased number of channels at the cell sur-
neonatal salt wasting with hypotension despite mark- face and hence, increased channel activity (Schild et
edly elevated aldosterone levels; affected patients also al., 1996). The increased number of channels is due to
have marked hyperkalemia and metabolic acidosis. reduced clearance of ENaC from the cell surface with
There are autosomal recessive and autosomal dominant dramatically longer half-life (Shimkets et al., 1997).
forms of disease (Hanukoglu, 1991). Patients with the Two lines of inquiry have suggested mechanisms for
dominant form have heterozygous loss-of-function mu- the prolonged half-life of mutant channels (Figure 4).
tations in MR, with a variety of premature termination Inhibition of endocytosis via clathrin-coated pits by
and frameshift mutations identified in affected kindreds dominant-negative dynamin induces a phenocopy of the
(Geller et al., 1998). This partial loss of MR function electrophysiologic phenotype of Liddle syndrome, in-
impairs maximal salt reabsorption; moreover, as ENaC creasing Na1 current by markedly prolonging the half-
action establishes the electrical driving force for K1 and life of ENaC at the cell surface (Shimkets et al., 1997).
H1 secretion in the distal nephron, the reduced ENaC In parallel, two WW domain–containing proteins, Nedd4-1
activity impairs K1 and H1 secretion, accounting for the (Staub et al., 1996) and Nedd4-2 (Kamynina et al., 2001)
observed hyperkalemia and metabolic acidosis. have been identified that specifically interact with the
These findings indicate that two normal copies of MR PPPXY sequence of ENaC subunits. These proteins
are required for normal salt homeostasis in the neonatal have ubiquitin ligase domains, suggesting that interac-
period. However, upon assumption of a normal salt-rich tion with ENaC subunits leads to their ubiquitination,
diet, these patients typically become entirely asymp- targeting ENaC for degradation. Consistent with this
tomatic and show no obvious phenotypic consequence proposal, expression of dominant-negative Xenopus
(Geller et al., 1998). This illustrates a dramatic example (Abriel et al., 1999) or mammalian Nedd4-2 (Kamynina
of interactions among genotype, age, and environment, et al., 2001), containing the WW domain without the
with the mutation being potentially lethal in the neonatal ubiquitin ligase domain, also prolongs the half-life of
period, but causing no evident disease among adults. wild-type ENaC. These findings indicate that an in-
creased number of ENaC at the cell surface is sufficient
to produce hypertension in humans. The mechanism, asMutations Altering Renal Ion Channels
and Transporters for other Mendelian forms of hypertension, is a primary
increase in net renal salt balance.Liddle Syndrome
Liddle syndrome is characterized by autosomal domi- Recessive PHAI
Loss-of-function mutations in any of the three differentnant transmission of early onset hypertension associ-
ated with hypokalemic alkalosis, suppressed plasma ENaC subunits cause the autosomal recessive form of
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PHAI (Chang et al., 1996; Strautnieks et al., 1996). Like normal or only mildly reduced magnesium levels. These
dominant PHAI, the recessive form features life-threat- patients often present with premature delivery and life-
ening salt wasting and hypotension in the neonatal pe- threatening hypotension in the neonatal period. This dis-
riod with hyperkalemia and metabolic acidosis, despite ease is caused by mutations in any of three genes that
high levels of aldosterone. Unlike patients with dominant are required for normal salt reabsorption in the thick
disease, however, these patients do not improve with ascending limb of Henle (TAL, Figure 1).
age, typically requiring continued massive salt supple- Mutations resulting in loss of function of the apical
mentation and treatment for hyperkalemia. Expression Na-K-2Cl cotransporter impair flux of salt across the
studies have confirmed that these mutations impair apical membrane, resulting in marked salt wasting, with
ENaC function. The pathophysiologic sequence is simi- consequent activation of the renin-angiotensin system
lar to that for dominant PHAI; in this case, despite activa- and hypokalemic alkalosis (Simon et al., 1996b). Muta-
tion of MR by high levels of aldosterone, the normal tions in two other genes produce highly similar pheno-
target for MR activation, ENaC, is missing, resulting in types (Simon et al., 1996c, 1997). One of these encodes
severe salt wasting and impaired K1 and H1 secretion. the ATP-sensitive K1 channel ROMK, which directs ef-
In addition to these effects on renal salt handling, flux of K1 across the apical membrane of the TAL (Figure
physiologic studies of mice and humans have indicated 1). Mutations in this K1 channel cause salt wasting in
a role for ENaC in the clearance of fluid from the surface the following fashion: Fluid entering the TAL has high
epithelium of the lung. Mice with targeted knock-out of concentrations of Na1 and Cl2 but low concentrations of
ENaC subunits have the PHAI phenotype and, in addi- K1. Therefore, stochiometric flux of Na1 and K1 into the
tion, have respiratory failure due to impaired clearance cell via the cotransporter would rapidly deplete K1 levels
of lung water (Hummler et al., 1996; Barker et al., 1998) in the luminal fluid, preventing efficient reabsorption of
Investigation of humans with PHAI have demonstrated Na1 and Cl2. This situation is avoided by the recycling
a similar, though less disabling, pulmonary defect (Kerem of K1 entering the cell back into the lumen. Mutations
et al., 1999). in ROMK in Bartter syndrome implicate this channel as
Gitelman and Bartter Syndromes required for K1 recycling, and demonstrate that in its
Hypokalemia with metabolic alkalosis and so-called nor- absence, salt reabsorption is markedly impaired. Bartter
mal blood pressure is a feature of a group of autosomal syndrome type 3 is caused by mutations in the Cl2 chan-
recessive disorders with diverse manifestations. Pa- nel CLCNKB (Simon et al., 1997). Salt entering the cell
tients can present in the neonatal period with life-threat- via the Na-K-2Cl cotransporter on the apical membrane
ening hypotension due to renal salt wasting or can have must exit across the basolateral membrane. Na1 exits
disease that is only diagnosed incidentally. Much of the via the Na1/K1 ATPase, but the mechanism of Cl2 exit
confusion regarding the diagnosis and classification of had been unclear. A substantial fraction of Bartter syn-
these patients has been resolved by molecular genetic drome kindreds have loss-of-function mutations in the
studies that have demonstrated mutations in 4 different Cl2 channel encoded by CLCNKB, implicating this chan-
genes that underlie this trait. In all cases, the disease nel in the exit step for chloride (Figure 1).
is caused by mutations that result in renal salt wasting.
The mildest of these disorders is Gitelman syndrome,
Other Mendelian Forms of Hypertension
which is genetically homogeneous and caused by loss-
There are several additional Mendelian hypertensive
of-function mutations in the gene encoding the thiazide-
syndromes for which the molecular mechanism has yetsensitive Na-Cl cotransporter of the DCT (Simon et al.,
to be defined. Pseudohypoaldosteronism type II (PHAII)1996a). Patients with this disorder typically present in
features hypertension with hyperkalemia despite other-adolescence or adulthood with neuromuscular signs
wise normal renal function. Patients have suppressedand symptoms and have blood pressure that is lower
plasma renin activity and a variety of other associatedthan the general population; in addition, they have low
findings. This syndrome is caused by mutations in atserum Mg21 and low urinary Ca21 levels (Bettinelli et al.,
least three different genes that have been mapped to1992). The salt wasting from the DCT leads to activation
chromosome 1q31-42, 12p13, and 17p11-q21 (Mans-of the renin-angiotensin system; in this case activation
field et al., 1997; Disse-Nicodeme et al., 2000).of MR is able to augment ENaC activity, defending salt
Hypertension with brachydactyly features severe hy-homeostasis at the expense of increased secretion of
pertension with abnormal skeletal development in theH1 and K1.
hand and wrist. There are no associated distinguishingLinkage studies in large inbred kindreds have docu-
biochemical features. This syndrome is mapped to chro-mented that these mutations indeed lower blood pres-
mosome 12p12.2-11.2 (Schuster et al., 1996a). As dele-sure, providing formal proof that even the modest salt
tions in this same interval can result in brachydactylywasting of this disease reduces blood pressure (Cruz
without hypertension (Bahring et al., 1997), it is temptinget al., 2001). The finding that mutations in this gene alter
to speculate that this syndrome results from alteredrenal Ca21 and Mg21 homeostasis is of some surprise,
function of contiguous genes.indicating heretofore unappreciated links between ac-
Finally, dominant-negative missense mutations intivity of this cotransporter and the handling of these
the peroxisome proliferator–activated receptor gammadivalent cations. Interestingly, heterozygous mutation
(PPARg) have been found in three patients with a syn-carriers maintain normal blood pressure, but consume
drome of insulin resistance, diabetes mellitus, and hy-substantially larger quantities of salt, indicating a com-
pertension (Barroso et al., 1999). The presence of ele-pensated defect (Cruz et al., 2001).
vated blood pressure in this syndrome is consistent withBartter syndrome is distinguished from Gitelman syn-
drome by hypercalciuria (increased urinary calcium) and the hypotensive effects of thiazolidinediones, a novel
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class of insulin-sensitizing agents that activate PPARg. tion. The lack of consistent reproducibility of these stud-
ies highlights the difficulties in genetic investigation ofThe molecular mechanisms linking PPARg activity to
blood pressure are presently uncertain. multifactorial traits. It seems apparent that firm conclu-
sions will require consistent replication of results in largeUnderstanding the molecular mechanisms underlying
hypertension in these disorders seems certain to pro- and rigorously characterized populations that are well
suited for detecting alleles imparting small effects. Suchvide new insight into pathways that regulate blood
pressure. populations would include cohorts of unrelated individu-
als as well as family-based studies that would allow use
of tests of transmission disequilibrium. These latter testsGenetic Studies in Essential Hypertension
minimize the chance of false-positive associations aris-Although the Mendelian traits described above have
ing from population admixture of individuals of differentquantitatively large effects in affected individuals, be-
genetic backgrounds (Spielman and Ewens, 1996).cause of their rarity, they likely account for a very small
Recently, the results of several genome-wide linkagefraction of the variation in blood pressure in the general
analyses have been published. Most of these have foundpopulation. Efforts to identify genes predisposing to hy-
no evidence for linkage that meets thresholds for signifi-pertension in the general population to date have largely
cance at the genome-wide level. Two studies analyzingfocused on analysis of candidate loci in pathways impli-
blood pressure as a quantitative trait have reported sig-cated in blood pressure variation; more recently, several
nificant linkage to either chromosome 2 or chromosomestudies have performed a genome-wide analysis of link-
17 (Hsueh et al., 2000; Levy et al., 2000). The latter locus,age, comparing the inheritance of each chromosome
interestingly, overlaps an interval underlying pseudohy-segment to phenotypes such as hypertension or blood
poaldosteronism type II (Mansfield et al., 1997), and thepressure. Candidate gene studies have typically com-
syntenic interval is linked to blood pressure in rat (Hilbertpared the prevalence of hypertension or the level of
et al., 1991; Jacob et al., 1991), raising the possibilityblood pressure among individuals of contrasting geno-
that all might reflect mutations in the orthologous gene.types at the candidate locus. Among such studies, com-
Nonetheless, in aggregate, genome-wide analyses ofmon variants in genes of the renin-angiotensin system,
linkage in humans to date have not consistently impli-the same pathway implicated in Mendelian forms of
cated particular chromosome intervals, suggesting ahypertension, have provided some evidence of effect.
model in which there may be many loci, each impartingFor example, a variant in the angiotensinogen gene
small effects on the trait, in the general population.(M235T) is associated with higher circulating angioten-
sinogen levels and hypertension in several but not all
populations (Jeunemaitre et al., 1992a; Corvol et al., Insights from Animal Models
In addition to human studies, investigation of spontane-1999; Staessen et al., 1999). This variant is in strong
linkage disequilibrium with another variant near the tran- ous and engineered animal models of hypertension hold
promise for understanding the long-term regulation ofscription start site that has been proposed to result in
increased transcription of the gene (Inoue et al., 1997). blood pressure. A number of inbred animal models of
hypertension have had blood pressure quantitative traitInterestingly, a mouse model featuring increased ex-
pression of the angiotensinogen gene demonstrates ele- loci (QTLs) mapped; to date, however, only one of these
has been identified at the molecular level, altering adre-vated blood pressure, indicating a plausible mechanism
(Takahashi and Smithies, 1999). Similarly, a common nal mineralocorticoid production (Rapp, 2000).
More instructive thus far have been genetically engi-variant in the angiotensin converting enzyme gene (ACE)
is strongly associated with variations in ACE levels. Al- neered mice in which gene activities have been specifi-
cally increased or decreased (Takahashi and Smithies,though initial linkage and association studies were nega-
tive, recent analyses of two Caucasian cohorts have 1999). Although a detailed discussion is beyond the
scope of this review, these models have often providedindicated significant association of common ACE alleles
to blood pressure variation in males (Jeunemaitre et new insight into blood pressure control. For example,
mice deficient in a variety of gene products, includingal., 1992b; Fornage et al., 1998; O’Donnell et al., 1998).
Nonetheless, the varied results of these studies suggest the bradykinin B2 receptor, the D1A and D3 dopamine
receptors, the atrial natriuretic peptide and its receptors,that these variants impart, at most, very modest effects.
A variant in the b subunit of ENaC (T594M) has been endothelial nitric oxide synthase, or even the potent
vasoconstrictor endothelin-1 and the endothelin type-Bassociated with hypertension in a single study (Baker
et al., 1998). Other genes causing Mendelian syndromes receptor have elevated blood pressure (Kurihara et al.,
1994; Huang et al., 1995; Ohuchi et al., 1999; Cvetkovichave not to date been systematically studied for roles
in blood pressure variation in the general population. and Sigmund, 2000). Conversely, in other cases, muta-
tions have had surprisingly little or no effect on bloodMany other loci have been studied as candidates and
reported to show significant association with blood pressure. For example, mice with either increased or
decreased activity of the b1-adrenergic receptor, whichpressure or hypertension in single studies. It is important
to point out that for most of these candidates, many mediates catecholamine-mediated increases in heart
rate and contractility, have normal blood pressure, indi-genetic studies have also been negative, leaving the
contribution of these loci to blood pressure variation in cating the ability of other physiologic systems to com-
pensate for alterations in cardiac function (Rohrer etthe general population in some doubt (Corvol et al.,
1999; Niu et al., 1999; Luft, 2000). At best, common al., 1996). In other cases, mouse models have provided
confirmation of human findings and have provided op-variants identified to date likely account for a very small
fraction of the variance in the trait in the general popula- portunity for further physiologic investigation that would
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be difficult or impossible to perform in humans (Taka- the known acquired forms of hypertension, which also
feature defects in this pathway. For example, aldoste-hashi and Smithies, 1999). While the physiologic link
rone-producing adenomas and licorice intoxication bothbetween altered gene products and hypertension is not
increase activation of the mineralocorticoid receptor,presently understood in all these models, it is worth
leading to salt retention. Similarly, constriction of justnoting that in all cases in which renal physiology has
one or both renal arteries, as occurs in renal artery steno-been examined, abnormalities in renal sodium handling
sis, is sufficient to produce hypertension via activationaccompany the hypertension (Shesely et al., 1996; Ga-
of the renin-angiotensin system. Aortic coarctation andriepy et al., 2000; Plato et al., 2000). It seems apparent
pheochromocytoma similarly decrease renal perfusion,that the study of model systems will continue to provide
thereby activating the renin-angiotensin system. Renin-novel insight into the physiology of blood pressure
producing tumors and high-estrogen birth control pillscontrol.
respectively increase levels of renin and its substrate
angiotensinogen, leading to elevated blood pressure.Implications
Reduction of glomerular filtration rate with developmentTo date, genetic studies have identified a substantial
of end-stage renal disease impairs renal salt and waternumber of genes in which rare mutations impart large
excretion. The finding that all of the known inherited andeffects on blood pressure, providing new insight into
acquired forms of hypertension operate via this pathwaythe causes of hypertension. Conversely, genetic studies
affords the compelling speculation that the commonof the general population have thus far been relatively
forms of hypertension in the general population will alsodisappointing, with no variants identified that account
be caused by direct or indirect alteration of net saltfor a substantial effect. These latter shortcomings sug-
balance.gest either that there are no single loci that account for
This suggestion is of some surprise for two reasons.a large fraction of the variation in blood pressure in the
First, hemodynamic studies of patients with commongeneral population or that the phenotypes and models
forms of hypertension typically demonstrate a normalapplied have been inadequate to detect them. In this
cardiac output with elevated systemic vascular resis-regard, the recent use of quantitative blood pressure as
tance, not the hemodynamic pattern one might antici-a phenotype for linkage studies in the Framingham Heart
pate from primary vascular volume overload (Bello etStudy has been encouraging (Levy et al., 2000). None-
al., 1967). Nonetheless, work in experimental animalstheless, if there are truly many loci which each impart
has demonstrated that steady-state hemodynamicsvery small effects on blood pressure in the population,
cannot be used to determine the primary derangementthe identification of these loci may ultimately add little to
underlying hypertension. For example, administration ofthe diagnosis and treatment of this disease in individual
aldosterone results initially in an increase in intravascu-patients. In this case, the major contributions from hu-
lar volume and cardiac output. In a short period of time,man genetic studies will be the identification of path-
however, tissues respond to perfusion that exceedsways and mechanisms involved in the long-term regula-
their metabolic demand by increasing their vascular re-tion of blood pressure as a means of defining rational
sistance, redirecting blood flow centrally. This local au-
targets for therapeutic intervention.
toregulation of blood flow increases renal perfusion, re-
Given the diversity of physiologic systems that can
sulting in renal salt loss and returning intravascular
influence blood pressure, it is striking that all Mendelian
volume and cardiac output to normal levels. Nonethe-
forms of hypertension and hypotension solved to date less, elevated blood pressure persists due to the higher
converge on a final common pathway, altering blood systemic vascular resistance (Figure 2). Critically, these
pressure by changing net renal salt balance (Figures 1 observations indicate that the primary cause of hyper-
and 2). These findings clearly establish the role of altered tension cannot be determined by assessment of the
salt homeostasis in blood pressure variation in humans steady-state hemodynamic pattern. Second, increased
and underscore the key role of the kidney in the long- activation of ENaC is commonly expected to lead to
term determination of blood pressure. It is worth noting hypokalemia and metabolic alkalosis, as is typically
that most of the known Mendelian forms of high and seen in aldosterone-producing adenomas, yet such
low blood pressure have now been solved, indicating findings are not common among patients with essential
that these findings do not reflect an obvious selection hypertension. Studies of Mendelian forms of hyperten-
bias. These findings appear to extend as well to animal sion have demonstrated that these features are by no
models of hypertension—when renal physiology has means obligatory, or even frequent, occurrences in pa-
been scrutinized, abnormal renal sodium handling is tients with hypertension attributable to increased ENaC
implicated as a mechanism of hypertension. activity (Rich et al., 1992; Botero-Velez et al., 1994; Geller
These molecular genetic findings are consistent with et al., 2000). Indeed, in recent years it has been appreci-
a large body of physiologic work that has shown the ated that cases of aldosterone-producing adenomas
key role of the kidney in the long-term determination of have been overlooked in patients who do not have these
blood pressure. For example, Guyton (1991) argued from signs (Gordon et al., 1994).
systems analysis, as well as experimental physiologic It is worth emphasizing that, despite arguments for
observations, that sustained hypertension ultimately re- important roles of other electrolytes such as K1 and
quires the active participation of the kidney, owing to Ca21 in blood pressure determination, for all the Mende-
the kidney’s normal ability to respond to increased per- lian traits studied, the single factor that consistently
fusion pressure with elimination of salt and water until predicts the direction of blood pressure is net salt bal-
blood pressure is restored to normal levels. Moreover, ance. Thus, Mendelian hypertensive and hypotensive
syndromes can both feature either hypokalemia or hyper-these genetic findings are also in accord with all of
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kalemia. Similar considerations apply to calcium han- terolemia led to use of highly efficacious HMGCoA reduc-
dling. In all cases, however, the direction of blood pres- tase inhibitors in the general population for prevention of
sure is predicted by the effect on net salt balance. myocardial infarction, despite the fact that most treated
Why should variation in renal salt reabsorption play individuals do not have identified mutations in the path-
such a central role in blood pressure determination? It ways regulating plasma cholesterol levels.
is tempting to speculate that our species’ evolution in Finally, findings in genetic forms of hypertension imply
the notoriously salt-poor environment of sub-Saharan that agents that alter renal salt handling address funda-
Africa provided strong adaptive advantage to alleles that mental abnormalities that may operate as well in more
promoted avid salt and water retention. Following the common forms of hypertension. These observations
diaspora of humans to salt-rich environments, these suggest that such medications should continue to play
same alleles that were of selective value in our ancestral an important role in the treatment of hypertension. More-
environment may now contribute to elevated blood over, the recognition of toxicities that unavoidably ac-
pressure and its attendant morbid consequences. This company complete antagonism of specific targets in
observation may explain the increased prevalence of this pathway may support the clinical use of lower doses
hypertension among individuals of more recent African of multiple medications rather than the typical practice
descent. of using increasing doses of single agents to attempt
The identification of the molecular mechanisms of to achieve desired blood pressures.
blood pressure variation has implications for the devel- While investigation of the molecular genetics of hyper-
opment and use of antihypertensive treatments. For ex- tension remains in its infancy, substantial progress has
ample, patients completely lacking a specific ion chan- been made in identifying fundamental pathways under-
nel provide a useful model of the clinical effects that lying disease pathogenesis. Future progress will con-
can be expected from pharmacologic inhibition of that tinue to come from molecular genetic studies of humans,
same channel. Thus, from the phenotype of patients as well as animal models of blood pressure variation. It
lacking the K1 channel ROMK and the Cl2 channel is anticipated that identification of the inherited determi-
CLCNKB, one can predict that selective antagonists of nants of blood pressure variation will explain disease
these channels would be potent antihypertensive di- pathophysiology, lead to preclinical diagnostic tests,
uretic agents. Moreover, the absence of phenotypic ef- and identify targets and pathways for novel therapeutic
fects outside the kidney in genetically deficient subjects interventions.
predicts that these pharmacologic agents would not
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